ACXP — Acurx Pharmaceuticals, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-06-25.
Performance
Technicals
Others in Healthcare
Measured signals that fired on ACXP
| date | signal | measured base rate |
|---|---|---|
| 2026-04-17 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-03-11 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2025-01-06 | LUCI DAVID P President and CEO | Open-market purchase | 49.3K | 1.02 | 50.2K |
| 2025-01-06 | DELUCCIA ROBERT J Director | Open-market purchase | 49.3K | 1.02 | 50.2K |
| 2025-01-06 | Scodari Joseph C Director | Open-market purchase | 24.6K | 1.02 | 25.1K |
| 2025-01-06 | Sailer Carl Director | Open-market purchase | 24.6K | 1.02 | 25.1K |
| 2025-01-06 | Donohue James J. Director | Open-market purchase | 9.9K | 1.02 | 10.0K |
| 2025-01-06 | DEAN JACK H Director | Open-market purchase | 9.9K | 1.02 | 10.0K |
| 2024-01-19 | Sailer Carl Director | Option exercise | 19.7K | 3.55 | 70.1K |
| 2024-01-03 | DELUCCIA ROBERT J Director | Option exercise | 19.7K | 3.55 | 70.1K |
| 2024-01-03 | LUCI DAVID P President and CEO | Option exercise | 19.7K | 3.55 | 70.1K |
| 2023-12-22 | DELUCCIA ROBERT J Director | Gift | 30.0K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| JANE STREET GROUP, LLC | 202.7K | 54.6K |
| VANGUARD CAPITAL MANAGEMENT LLC | 115.4K | 31.1K |
| GEODE CAPITAL MANAGEMENT, LLC | 92.1K | 24.8K |
| VANGUARD FIDUCIARY TRUST CO | 60.1K | 16.2K |
| Prospect Financial Services LLC | 51.1K | 13.8K |
| MORGAN STANLEY | 24.1K | 6.5K |
| UBS Group AG | 23.4K | 6.3K |
| WELLS FARGO & COMPANY/MN | 8.5K | 2.3K |
| Westside Investment Management, Inc. | 6.1K | 1.6K |
| NBC SECURITIES, INC. | 5.6K | 1.5K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Acurx Pharmaceuticals GAAP EPS of -$0.53 misses by $0.19 · 2026-08-14
- Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update · 2026-08-14
- Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics · 2026-08-12
Ask the AI about ACXP
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →